MX2012000768A - Derivados de tazaroteno. - Google Patents

Derivados de tazaroteno.

Info

Publication number
MX2012000768A
MX2012000768A MX2012000768A MX2012000768A MX2012000768A MX 2012000768 A MX2012000768 A MX 2012000768A MX 2012000768 A MX2012000768 A MX 2012000768A MX 2012000768 A MX2012000768 A MX 2012000768A MX 2012000768 A MX2012000768 A MX 2012000768A
Authority
MX
Mexico
Prior art keywords
derivatives
tazarotene
pharmaceutical compositions
refers
formation
Prior art date
Application number
MX2012000768A
Other languages
English (en)
Spanish (es)
Inventor
Hans Hofland
Xue Ge
Hansen Wong
Wendy Huang Chern
Michael J Bishop
Xin Frank Cai
Alan Colborn
Original Assignee
Stiefel Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Laboratories filed Critical Stiefel Laboratories
Publication of MX2012000768A publication Critical patent/MX2012000768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012000768A 2009-07-16 2010-07-16 Derivados de tazaroteno. MX2012000768A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21379409P 2009-07-16 2009-07-16
US27225709P 2009-09-04 2009-09-04
PCT/US2010/042225 WO2011009023A1 (en) 2009-07-16 2010-07-16 Tazarotene derivatives

Publications (1)

Publication Number Publication Date
MX2012000768A true MX2012000768A (es) 2012-02-13

Family

ID=43449815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000768A MX2012000768A (es) 2009-07-16 2010-07-16 Derivados de tazaroteno.

Country Status (16)

Country Link
US (3) US20120115909A1 (enExample)
EP (1) EP2453746A4 (enExample)
JP (1) JP5635090B2 (enExample)
KR (1) KR101536806B1 (enExample)
CN (1) CN102595892B (enExample)
AU (1) AU2010273261B2 (enExample)
BR (1) BR112012001680A2 (enExample)
CA (1) CA2768015C (enExample)
EA (1) EA022322B1 (enExample)
IL (1) IL217519A (enExample)
IN (1) IN2012DN00546A (enExample)
MX (1) MX2012000768A (enExample)
NZ (1) NZ598240A (enExample)
SG (1) SG177579A1 (enExample)
WO (1) WO2011009023A1 (enExample)
ZA (1) ZA201200253B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105050D0 (en) 2011-03-25 2011-05-11 Iiaa Ltd Pharmaceutical agent
CN111298120A (zh) * 2011-06-24 2020-06-19 格里生物公司 炎性病症的预防和治疗
CN106918676B (zh) * 2015-12-24 2020-08-11 重庆华邦制药有限公司 分离测定他扎罗汀倍他米松乳膏中两种药物含量及有关物质的方法
CN107176945B (zh) * 2016-03-11 2021-06-08 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用
WO2017152725A1 (zh) * 2016-03-11 2017-09-14 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801593A (en) * 1979-09-13 1989-01-31 Burroughs Wellcome Co. Chemotherapeutic agents
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5399561A (en) * 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
HUT63405A (en) 1990-10-09 1993-08-30 Allergan Inc Process for producing acetylene derivatives substituted with chromanyl, thiochromanyl or tetrahydroquinolinyl group and having retinoid-like activity, as well as pharmaceutical compositions comprising same as active ingredient
EP0571546B1 (en) 1991-02-13 1996-10-16 Allergan, Inc. Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity
EP0577737A1 (en) 1991-03-26 1994-01-12 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
AU9259598A (en) * 1997-07-08 1999-02-08 Gist-Brocades B.V. Topical application of a combination of benzoyl peroxide and a second active ingredient
AU5132799A (en) * 1998-07-28 2000-02-21 Bershad, Susan Short contact treatment of acne and photoaging with topical retinoids
US6048902A (en) * 1999-02-12 2000-04-11 Lebwohl; Mark G. Short contact treatment of psoriasis with topical retinoids
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
CN1210041C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
ITMI20050357A1 (it) * 2005-03-08 2006-09-09 Solmag S P A Procedimento di preparazione del tazarotene
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
MXPA06008988A (es) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
EA200970724A1 (ru) * 2007-02-01 2010-02-26 Сол-Джел Текнолоджиз Лтд. Композиции для местного применения, содержащие пероксид и ретиноид

Also Published As

Publication number Publication date
IL217519A (en) 2015-06-30
IL217519A0 (en) 2012-02-29
CN102595892B (zh) 2014-09-10
US20140357669A1 (en) 2014-12-04
US20140357672A1 (en) 2014-12-04
KR20120056821A (ko) 2012-06-04
EP2453746A4 (en) 2013-04-24
SG177579A1 (en) 2012-02-28
US20120115909A1 (en) 2012-05-10
JP2012533564A (ja) 2012-12-27
AU2010273261A1 (en) 2012-02-02
CA2768015C (en) 2016-03-15
US9062037B2 (en) 2015-06-23
EA022322B1 (ru) 2015-12-30
CA2768015A1 (en) 2011-01-20
JP5635090B2 (ja) 2014-12-03
CN102595892A (zh) 2012-07-18
IN2012DN00546A (enExample) 2015-06-12
KR101536806B1 (ko) 2015-07-14
NZ598240A (en) 2013-10-25
BR112012001680A2 (pt) 2015-09-01
EP2453746A1 (en) 2012-05-23
ZA201200253B (en) 2013-05-29
EA201270176A1 (ru) 2012-08-30
WO2011009023A1 (en) 2011-01-20
AU2010273261B2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
CO6571913A2 (es) Derivados de fumarato de ácido graso y sus usos
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CO7111303A2 (es) Compuestos de microarn y métodos de modulación de la actividad de mir-21
MX386820B (es) Microcápsulas lipídicas que comprenden de preferencia un retinoide y composición que las contiene, su procedimiento de preparación y su uso en dermatología.
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CL2013002612A1 (es) Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno.
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
BR112013028534A2 (pt) compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
UY34123A (es) Método para la oxidación catalítica de la celulosa y método para hacer un producto de celulosa.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
CR20140553A (es) Compuestos de fenoxietil piperidina
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
MX2019003090A (es) Compuestos de microarn y metodos para modular la actividad de mir-21.
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
UY33992A (es) Métodos para modificar la biosintesis de la lignina y mejorar la digestibilidad
CL2014000289A1 (es) Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica.
PA8846201A1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
BRPI0911024A2 (pt) "método para produzir macarrão instantâneo"
CL2015000434A1 (es) Metodo para el tratamiento, prevencion o disminucion de la severidad de una condicion o trastorno no neoplasico de la piel que comprende administrar un compuesto derivado de retinoides; composicion dermica que comprende los derivados de retinoide.
GT201200216A (es) Nuevos derivados terciarios de 8-hidroxiquinolina-7carboxamida y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration